Project funded by:
What is SpIDnet?
It assesses the impact of the two main groups of pneumococcal vaccines currently recommended:
- Conjugate vaccines (PCVs), which currently cover 10 or 13 serotypes
- Polysaccharide vaccines such as the 23-valent vaccine (PPV23).
From 2012 to 2018, 15 partner institutions from 10 EU Member States participated in the first phase of SpIDnet. Coordinated by Epiconcept, it was dedicated to the evaluation of conjugate pneumococcal vaccines.
From 2015 to 2018, the I-MOVE + pneumococcus network, funded by the European Commission's Horizon 2020 programme, complemented SpIDnet.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446